A
Menu
July 24, 2024 article Open access

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

Neurology and Therapy

DOI: 10.1007/s40120-024-00647-0 Full text (OA) OpenAlex

Authors 0

  1. Author list not loaded yet.

Cited by 0 stored of 10

References 2

2 results